Genetics of Schizophrenia: Recent Advances
By Amy Eisener, BS, Michele T. Pato, MD, Helena Medeiros, MSW, Celia Carvalho, MS, and Carlos N. Pato, MD
Neuropsychiatric Update: Neuroimaging Schizophrenia
By Shawn J. Kile, MD
Ethical Issues in Schizophrenia: Considerations for Treatment and Research
By Laura B. Dunn, MD
Genetics and Its Use in Alzheimer’s Disease
Joseph H. Lee, DRPH and Richard Mayeux, MD, MSC
Psychosocial Interventions for Bipolar Disorder: A Review of Literature and Introduction of the Systematic Treatment Enhancement Program
David J. Miklowitz, PhD and Michael W. Otto, PhD
Invited Commentary: Understanding the Fibromyalgia Syndrome
I. Jon Russell, MD, PhD. and Christopher J. Wohlberg, MD, PhD
Evidence-Based Treatment of Psychiatric Disorders with Comorbid Medical Illnesses: The Need for Large Simple Clinical Trials
Warren D. Taylor, MD, P. Murali Doraiswamy, M.B.,B.S., and K. Ranga R. Krishnan, M.B.,B.S
Panel Discussion
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
By William H. Carson, MD, Hisashi Kitagawa, PhD, and Charles B. Nemeroff, MD, PhD
Unmet Needs in the Treatment of Anxiety Disorders
By Mark H. Pollack, MD
Late-Life Anxiety Disorders
By Carl Salzman, MD
Understanding Psychiatric Disorders Through Functional Brain Imaging
By Clinton D. Kilts, PhD
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Studying Non-Human Primates: A Gateway to Understanding Anxiety Disorders
By Ned H. Kalin, MD
Advancing the Treatment of Anxiety Disorders: New Findings and Novel Uses for Atypical Antipsychotics
Valproate Use in Neuropsychiatric Disorders in the Elderly
By Pierre N. Tariot, MD
Divalproex in the Treatment of Migraine
By Frederick G. Freitag, DO
The Use of Divalproex in the Treatment of Addictive Disorders
By Hugh Myrick, MD and Kathleen T. Brady, MD, PhD
Schizophrenia and Valproate
By Leslie Citrome, MD, MPH
Divalproex in the Treatment of Bipolar Disorder
By Paul E. Keck, Jr, MD, and Susan L. McElroy, MD
The Efficacy of Divalproex for Partial Epilepsies
By Michael C. Smith, MD
Divalproex and Epilepsy
By L. James Willmore, MD
Pharmacology of Valproate
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
Paroxetine Treatment of Mood and Anxiety Disorders in Children and Adolescents
By Karen Dineen Wagner, MD, PhD
Clinical Management of Perinatal Depression: Focus on Paroxetine
By D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD
Paroxetine Treatment of Mood Disorders in Women: Premenstrual Dysphoric Disorder and Hot Flashes
By Kimberly A. Yonkers, MD
Paroxetine Treatment of Depression in Late Life
By Charles F. Reynolds III, MD
Paroxetine Use in Medically Ill Patients
By Steven Stout, MD, PhD, Wendy I. Somerset, MD, Andrew Miller, MD, and Dominique L. Musselman, MD, MS
Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective
By Murray B. Stein, MD, FRCPC
Obsessive-Compulsive Disorder: Implications of the Efficacy of an SSRI, Paroxetine
By Philip T. Ninan, MD
Treatment of Posttraumatic Stress Disorder: The Impact of Paroxetine
By Jonathan R.T. Davidson, MD
Paroxetine Treatment of Generalized Anxiety Disorder
By David V. Sheehan, MD, MBA, and C. Gloria Mao, PharmD
Treatment of Panic Disorder: Focus on Paroxetine
By Mark H. Pollack, MD and Alicia C. Doyle, BA
Paroxetine Treatment of Major Depressive Disorder
By Martin B. Keller, MD
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
By Clinton Kilts, PhD
Neuropharmacology of Paroxetine
Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine
Gender-Specific Differences in Depression and Treatment Response
By Susan G. Kornstein, MD, Diane M. E. Sloan, PharmD, and Michael E. Thase, MD
New Advances in the Management of Anxiety Disorders
Neurobiology and Mechanisms of Antidepressant Treatment Response in Anxiety
By Philip T. Ninan, MD, Sarah A. Feigon, PhD, and Bettina Knight, RN
Strategies for Treatment-Resistant Depression
By Christos Ballas, MD, Jeffrey P. Staab, MD, MS, and Dwight L. Evans, MD
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
Remission as the Critical Outcome of Depression Treatment
By Michael E. Thase, MD, Diane M. E. Sloan, PharmD, and Susan G. Kornstein, MD
New Developments in Depression and Anxiety Disorders
Raising the Expectations of Long-Term Treatment Strategies in Anxiety Disorders
Can We Distinguish Anxiety From Depression?
By David S. Baldwin, FRCPsych, Dwight L. Evans, MD, Robert M. A. Hirschfeld, MD, and Siegfried Kasper, MD